A5004578546- SARS-CoV-2 and COVID-19 Research
- Cancer Treatment and Pharmacology
- COVID-19 Clinical Research Studies
- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- COVID-19 and healthcare impacts
- Brain Metastases and Treatment
- Ethics in Clinical Research
- Immunotherapy and Immune Responses
- Glioma Diagnosis and Treatment
- Vaccine Coverage and Hesitancy
- Long-Term Effects of COVID-19
- Academic integrity and plagiarism
- Academic Publishing and Open Access
- RNA Interference and Gene Delivery
- Colorectal Cancer Treatments and Studies
- Lung Cancer Research Studies
- Cancer Diagnosis and Treatment
- Cancer survivorship and care
- Patient-Provider Communication in Healthcare
- Frailty in Older Adults
- Hemoglobinopathies and Related Disorders
- Cutaneous Melanoma Detection and Management
- Monoclonal and Polyclonal Antibodies Research
Clinique Saint Jean Languedoc
2015-2025
Centre Antoine Lacassagne
2010-2023
Cancer Research Center
2014
Abstract Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses stimulation a third dose (D3) the same patients chronic lymphocytic leukemia ( n = 13), B cell non-Hodgkin lymphoma 14), multiple myeloma 16)). No unexpected novel side...
PURPOSE Platinum-based doublets with concurrent and maintenance bevacizumab are standard therapy for ovarian cancer (OC) relapsing after a platinum-free interval (PFI) >6 months. Immunotherapy may be synergistic chemotherapy. PATIENTS AND METHODS ATALANTE/ENGOT-ov29 (ClinicalTrials.gov identifier: NCT02891824 ), placebo-controlled double-blinded randomized phase III trial, enrolled patients recurrent epithelial OC, one to two previous chemotherapy lines, PFI Eligible were randomly...
The SARS-CoV-2 infection has spread rapidly around the world causing millions of deaths. Several treatments can reduce mortality and hospitalization. However, their efficacy depends on choice molecule precise timing its administration to ensure viral clearance avoid a deleterious inflammatory response. Here, we investigated IFN-γ, assessed by functional immunoassay, as predictive biomarker for risk hospitalization at an early stage or within one month prior infection. Individuals with IFN-γ...
Abstract Lessons Learned Results suggest that the combination of bevacizumab plus temozolomide is active in terms response rate, survival, performance, quality life, and cognition elderly patients with glioblastoma multiforme poor performance status. Whether this superior to alone remains be demonstrated by a randomized study. Background The optimal treatment (GBM) aged ≥70 years Karnofsky status (KPS) <70 not established. This clinical trial evaluated efficacy safety upfront (TMZ)...
Elderly patients with metastatic breast cancer have a prognosis and outcome that may be dependent on host of factors.We retrospectively analyzed 401 female who developed disease after the age 70 years in order to define potential prognostic factors for specific survival at time first recurrence.With median follow-up 60 months from recurrence, was 21.0 (95% CI 17.0-23.0). In multivariate analysis we demonstrated negative hormonal receptor status (p = 0.002), presence positive lymph nodes...
Autologous stem cell transplant (ASCT) after high-dose chemotherapy (HDT) increases overall survival when used in relapsed non-Hodgkin lymphoma (NHL) patients under 65 years old. Limited experience is available for older patients. We present a retrospective analysis of 73 consecutive aged over treated aggressive or by HDT with carmustine, etoposide, cytarabine and melphalan (BEAM) at full dosage followed ASCT. Patient data were obtained from medical charts two institutions. Median age was 67...
Abstract BACKGROUND Immunocompromised patients such as with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation a repeated stimulation third dose is needed. METHODS monitoring observatory was conducted in outpatients who were treated for lymphoid (LM) monitor both and cellular measured the day administration 3 mRNA again three four weeks. Elecsys ® Anti-SARS-CoV-2 immunoassay used asses level SARS-CoV-2...
Background: France's ethical and legal principles place general practitioners (GPs) at the forefront of cancer patient management, coordination, follow-up. The objective this study was to determine actual role GPs in follow-up phase as well perspectives on their GPs.Method: A multidisciplinary group researchers conducted qualitative based in-depth interviews 50 patients managed two centres. content analysis method used analyse data.Results: According interviewed for study, were relatively...